Thyroid Replacement (T4) Special Populations: A Prescriber's Summary

What Is the Thyroid Replacement (T4) Drug Class?

Thyroid replacement (T4) agents supply exogenous thyroxine to patients whose thyroid gland cannot produce adequate hormone. Levothyroxine, the synthetic sodium salt of L-thyroxine, is the near-universal prototype. It is converted peripherally to the active triiodothyronine (T3) by deiodinase enzymes, replicating the dominant pathway of endogenous thyroid hormone physiology.

The American Thyroid Association (ATA) 2014 hypothyroidism guidelines state: "Levothyroxine should be used in preference to other thyroid hormone preparations due to its consistent potency and long half-life." (ATA 2014)

Mechanism and Pharmacokinetics

Levothyroxine has a half-life of roughly 7 days, which produces steady plasma concentrations and allows once-daily dosing. Oral bioavailability ranges from 60% to 80% when taken fasting. Food, calcium, iron, and several medications reduce absorption meaningfully, which is why consistent fasting administration matters clinically.

T4 binds thyroid-binding globulin (TBG) in plasma. Only the free fraction (fT4, roughly 0.03% of total T4) is biologically active. Conditions that alter TBG levels, including pregnancy and estrogen therapy, change total T4 measurements without necessarily reflecting true hormone activity.

Available Formulations

• Oral tablets: Synthroid, Euthyrox, generic levothyroxine. Tablet-to-tablet bioavailability differences between brands are small but clinically significant in narrow-therapeutic-index patients; the FDA advises against switching formulations without retesting TSH in 6 to 8 weeks. (FDA Bioequivalence guidance)
• Soft-gel capsules (Tirosint): Improved bioavailability in patients with achlorhydria or on PPIs.
• Liquid solution (Tirosint-SOL): Useful for pediatric titration or patients with severe malabsorption.
• IV formulation: Used for myxedema coma; typical initial dose is 200 to 400 mcg IV as a loading dose.

Pregnancy: The Highest-Stakes Population

Hypothyroidism in pregnancy demands prompt, aggressive treatment. Maternal T4 is the sole source of thyroid hormone for the fetus during the first trimester (before fetal thyroid function begins at roughly 10 to 12 weeks). Undertreated hypothyroidism is associated with preterm birth, placental abruption, impaired fetal neurodevelopment, and lower childhood IQ scores. (NEJM 1999, Haddow et al.)

TSH Targets by Trimester

The ATA 2017 guidelines on thyroid disease in pregnancy specify trimester-specific TSH upper limits:

• First trimester: <2.5 mIU/L
• Second trimester: <3.0 mIU/L
• Third trimester: <3.5 mIU/L

The lower bound for all three trimesters is 0.1 mIU/L; suppressed TSH warrants dose reduction. (ATA 2017 Pregnancy Guidelines)

Dose Escalation in Pregnancy

Levothyroxine requirements increase by 25%, 50% in pregnancy, driven by rising TBG levels, increased renal iodine clearance, and placental T4 deiodination. In women with pre-existing hypothyroidism who become pregnant, many endocrinologists advise immediately increasing the daily dose by two additional doses per week (roughly a 29% increase) while awaiting formal TSH measurement. Monitoring frequency should be every 4 weeks through 20 weeks gestation, then once at 30 weeks.

Women with subclinical hypothyroidism (TSH 2.5 to 10 mIU/L, normal fT4) who are trying to conceive or are in early pregnancy should be treated with levothyroxine; the absolute TSH threshold for initiating treatment remains debated but most U.S. Endocrinologists treat when TSH exceeds 2.5 mIU/L in the first trimester. (Endocrine Society Clinical Practice Guideline)

Postpartum Dose Adjustment

After delivery, levothyroxine requirements typically return to pre-pregnancy levels within 6 to 8 weeks. TSH should be rechecked 6 weeks postpartum. Failing to reduce the dose risks iatrogenic thyrotoxicosis and its associated bone and cardiac effects.

Neonatal and Pediatric Hypothyroidism

Congenital Hypothyroidism

Congenital hypothyroidism (CH) affects approximately 1 in 2,000 to 3,000 live births. (AAP/Lawson Wilkins 2006) Early treatment is time-sensitive: neurodevelopmental outcomes are significantly better when levothyroxine is started within the first 2 weeks of life. The recommended starting dose for neonates with CH is 10 to 15 mcg/kg/day, with higher-end dosing for severe CH (undetectable T4 at diagnosis). The goal is to normalize serum T4 within 2 weeks and TSH within 4 weeks of treatment initiation.

A landmark analysis of 1,420 children with CH found that initial T4 levels above the normal mean were associated with higher IQ scores at age 7 to 10, supporting the current high-dose initiation strategy. (Selva et al., J Pediatr 2005)

Pediatric Dosing by Age

Weight-based dosing decreases per kilogram as children grow:

| Age group | Levothyroxine dose (mcg/kg/day) | |---|---| | 0 to 3 months | 10 to 15 | | 3 to 6 months | 8 to 10 | | 6 to 12 months | 6 to 8 | | 1 to 5 years | 5 to 6 | | 6 to 12 years | 4 to 5 | | 12 to 18 years | 2 to 3 | | Adults | 1.6 |

Tablets may be crushed and mixed with a small amount of water or breast milk (not soy formula, which impairs absorption) for infant administration. TSH and fT4 should be monitored every 1 to 3 months in the first year of life, then every 2 to 4 months until age 3, then every 6 to 12 months thereafter.

Elderly Patients: Cautious Initiation, Higher TSH Tolerance

Altered Thyroid Physiology with Age

Thyroid hormone metabolism slows with age. Older adults require lower daily doses (average 1.0 to 1.2 mcg/kg/day versus 1.6 mcg/kg/day in younger adults) and tolerate less pharmacodynamic variability. Serum TSH naturally drifts upward with age, and population studies indicate that a TSH of 4 to 7 mIU/L may be the physiologic norm for adults over 80. (Surks et al., JAMA 2007)

TSH Targets and Over-Treatment Risk

The conventional TSH target of 0.5 to 2.5 mIU/L is appropriate for healthy adults under 65. For adults aged 65 to 80, most guidelines accept a target of 1.0 to 4.0 mIU/L. For adults over 80, a TSH up to 6.0 to 7.0 mIU/L may be acceptable and aggressively chasing lower TSH values may cause net harm.

Subclinical hyperthyroidism from over-treatment carries measurable risk in older adults: a TSH <0.1 mIU/L is associated with a threefold increased risk of atrial fibrillation and accelerated bone loss. The Osteoporotic Fractures Study found that women with suppressed TSH had a fourfold higher risk of hip fracture. (JAMA 2001, Bauer et al.)

Initiation Strategy in Older Adults

Start at 25 mcg/day in adults over 65, or in any patient with known or suspected coronary artery disease. Increase in 12.5 to 25 mcg increments every 6 to 8 weeks. This is slower than the standard 4-week titration window used in younger patients. Check TSH 6 to 8 weeks after each adjustment.

Cardiac Disease: Managing Chronotropy and Oxygen Demand

Why Cardiac Patients Require Extra Caution

Thyroid hormone increases heart rate, myocardial contractility, and cardiac output. In patients with coronary artery disease, angina, or arrhythmia, abrupt normalization of TSH can precipitate angina, myocardial infarction, or accelerate a pre-existing tachyarrhythmia. The prescription principle is: start low, go slow.

Dose Protocol in Cardiac Patients

Begin at 12.5 to 25 mcg/day. Increase by 12.5 mcg every 4 to 6 weeks. Do not target low-normal TSH in patients with paroxysmal atrial fibrillation or recent acute coronary syndrome. In patients with severe coronary disease who are profoundly hypothyroid, some clinicians accept a TSH of 5 to 10 mIU/L as an interim target rather than risk destabilizing ischemic disease with rapid T4 correction.

The Endocrine Society's clinical practice guideline notes: "The initial levothyroxine dose should be lower in patients with cardiac disease or risk of cardiac disease, and the dose should be increased gradually." (Endocrine Society 2012)

Interaction with Cardiac Medications

• Warfarin: Levothyroxine potentiates anticoagulation by increasing catabolism of vitamin K-dependent clotting factors. INR should be checked 4 to 6 weeks after any levothyroxine dose change.
• Digoxin: Hypothyroid patients have elevated digoxin levels; as thyroid function normalizes, digoxin distribution volume increases and effective serum levels may fall, potentially requiring dose adjustment.
• Beta-blockers: Propranolol and atenolol reduce peripheral T4-to-T3 conversion. This reduces cardiovascular T3 burden and may blunt symptom response; beta-blockers do not replace levothyroxine therapy.

Malabsorption Syndromes and GI Conditions

Celiac disease, short bowel syndrome, bariatric surgery (Roux-en-Y gastric bypass), and inflammatory bowel disease all reduce levothyroxine absorption. Patients with these conditions typically require 20%, 30% higher doses than predicted by body weight. Tirosint soft-gel capsules or Tirosint-SOL liquid formulation may partially bypass absorption deficits that affect tablet dissolution. (Lahner et al., Eur J Endocrinol 2010)

Achlorhydria and PPI Use

Gastric acid facilitates T4 dissolution from tablets. Patients on proton-pump inhibitors show measurably higher TSH values at equivalent levothyroxine doses compared with acid-sufficient controls. One prospective study found that omeprazole use was associated with a TSH increase of 0.7 mIU/L on average. Switching these patients to liquid or soft-gel levothyroxine or increasing the tablet dose (often by 25 mcg) generally restores TSH to target.

Obesity and Weight-Based Dosing

In obese patients, dosing based on actual body weight (1.6 mcg/kg/day) can produce supraphysiologic doses. Evidence suggests using adjusted or ideal body weight for initial dose calculations, then titrating by TSH response. A retrospective analysis of 680 hypothyroid patients found that ideal body weight-based dosing reduced rates of over-treatment by 23% compared with actual body weight dosing. (Verga et al., J Endocrinol Invest 2012)

HealthRX Prescribing Framework: Starting Dose by Population

| Population | Starting dose | Titration interval | TSH target | |---|---|---|---| | Healthy adult <65 | 1.6 mcg/kg/day (full replacement) or 50 mcg | Every 4 to 6 weeks | 0.5 to 2.5 mIU/L | | Adult 65 to 80 | 25 to 50 mcg/day | Every 6 to 8 weeks | 1.0 to 4.0 mIU/L | | Adult >80 | 12.5 to 25 mcg/day | Every 8 weeks | 2.0 to 6.0 mIU/L | | Cardiac disease | 12.5 to 25 mcg/day | Every 4 to 6 weeks (conservative) | 1.0 to 4.0 mIU/L | | Pregnancy (pre-existing hypothyroidism) | Increase current dose ~29% immediately | Every 4 weeks through 20 weeks | <2.5 mIU/L (T1), <3.0 (T2), <3.5 (T3) | | Neonate (congenital hypothyroidism) | 10 to 15 mcg/kg/day | Every 1 to 3 months | Normalize fT4 within 2 weeks | | Malabsorption / PPI user | 1.6 mcg/kg/day (actual) + 25 mcg empiric increase, or switch formulation | Every 4 to 6 weeks | 0.5 to 2.5 mIU/L | | Obesity | 1.6 mcg/kg of ideal body weight | Every 4 to 6 weeks | 0.5 to 2.5 mIU/L |

Key Drug Interactions Across All Populations

Several interactions are consistent across every population and require specific management:

Absorption-Reducing Agents

The following agents should be separated from levothyroxine by a minimum of 4 hours:

• Calcium carbonate and calcium citrate: Both bind T4 in the GI lumen and reduce bioavailability by up to 40%.
• Ferrous sulfate (iron): Reduces levothyroxine absorption by 30%, 50%.
• Cholestyramine and colestipol: Bile acid sequestrants bind T4 in the gut; separate by at least 4 hours and recheck TSH after initiating.
• Sucralfate: Separate by 2 hours minimum.
• Antacids (aluminum/magnesium hydroxide): Separate by 4 hours.

Metabolism-Altering Agents

Rifampin, phenytoin, carbamazepine, and phenobarbital all induce hepatic enzymes that increase levothyroxine clearance. Patients starting these antiepileptics or anti-tuberculosis agents typically need a 25%, 50% dose increase, confirmed by TSH at 4 to 6 weeks. (Dong et al., Br J Clin Pharmacol 2011)

Sertraline and other serotonin-reuptake inhibitors may also increase levothyroxine requirements, though the mechanism is less well characterized.

Monitoring Parameters by Population

Consistent TSH monitoring anchors safe prescribing across all patient types. Key intervals:

• After any dose change: TSH at 6 to 8 weeks (4 weeks in pregnancy).
• Stable nonpregnant adults: TSH annually.
• Pregnancy: TSH every 4 weeks through 20 weeks gestation, then once at 30 weeks, and again at 6 weeks postpartum.
• Neonates with CH: TSH and fT4 every 1 to 3 months in year one.
• Pediatric patients beyond year one: Every 3 to 6 months until growth is complete, then annually.
• Elderly patients after dose change: TSH at 8 weeks given slower metabolic equilibration.

Free T4 adds clinical information when TSH is discordant with symptoms, when secondary (pituitary) hypothyroidism is suspected, or in early pregnancy before the feedback axis stabilizes.

Subclinical Hypothyroidism: Who Actually Needs Treatment?

Subclinical hypothyroidism (SCH) is defined as a TSH above the upper limit of normal with a normal fT4. Population prevalence is roughly 4%, 8% in iodine-sufficient regions. Treatment decisions depend on TSH level, age, symptoms, and cardiovascular risk.

TSH 4.5 to 10 mIU/L

Treat if: the patient is under 65 with symptoms, TPO antibodies are positive (predicts progression to overt hypothyroidism at 4%, 5%/year), the patient is pregnant or trying to conceive, or there is evidence of cardiac dysfunction. (Biondi and Cooper, NEJM 2012)

Observe without treatment if: the patient is over 70 and asymptomatic, because SCH at this age may represent age-appropriate TSH drift and the Thyroid Studies Collaboration (N=55,287) found no association between SCH and coronary heart disease in adults over 65. (Rodondi et al., JAMA 2010)

TSH >10 mIU/L

Most guidelines recommend treating all patients regardless of symptoms or age, given the increased risk of heart failure and coronary events at these TSH elevations.

Myxedema Coma: Emergency Dosing

Myxedema coma requires IV levothyroxine. Standard protocol:

• Loading dose: 200 to 400 mcg IV over 5 to 10 minutes (some authorities use 300 to 500 mcg in large-framed patients).
• Maintenance: 50 to 100 mcg IV daily until oral administration is possible.
• Many intensivists add IV liothyronine (T3) at 5 to 20 mcg every 8 hours for the first 24 to 48 hours, acknowledging that peripheral conversion is impaired in critical illness.
• Concurrent hydrocortisone 100 mg IV every 8 hours is standard until adrenal co-insufficiency is ruled out.

Mortality in myxedema coma ranges from 20% to 60% depending on comorbidities and time to diagnosis. (Mathew et al., Endocr Pract 2011)

Secondary and Central Hypothyroidism

In patients with pituitary or hypothalamic disease, TSH is not a reliable monitoring parameter because the pituitary itself is the source of dysfunction. Use free T4 as the primary monitoring test, targeting the mid-to-upper half of the reference range. Starting doses are the same as for primary hypothyroidism, but titration is guided entirely by fT4 and clinical symptoms rather than TSH.

Before starting levothyroxine in a patient with panhypopituitarism, replace cortisol first. Initiating T4 without adequate cortisol replacement can precipitate adrenal crisis by accelerating cortisol clearance.